<DOC>
	<DOC>NCT01776528</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of NGM282, both single dose and multiple doses, in normal healthy adult participants.</brief_summary>
	<brief_title>Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Males or females, between 18 and 65 years of age, inclusive BMI range is 2035 kg/m2, inclusive for the SAD Module, and 2535 kg/m2, inclusive for the MAD Module at Screening; In good health, determined by no clinically significant findings from medical history, physical exam, 12 lead ECG, clinical laboratory findings, and vital signs at Screening and Day 1 Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, or psychiatric disorder (as determined by the PI) History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>